Patients with diabetes may have kidney diseases other than the diabetickidneydisease.
2
Thus, HIF stabilization counteracts alterations in renal energy metabolism occurring in incipient diabetickidneydisease.
3
Context: Impaired vitamin D metabolism may contribute to the development and progression of diabetickidneydisease.
4
Aim: To analyse the efficacy and safety of endothelin receptor antagonists for people with diabetickidneydisease.
5
Purpose: Renal inflammatory response is involved in the development and progression of diabetickidneydisease (DKD).
6
Also, HO-1 expression is important in the pathogenesis of hypertension, diabetickidneydisease, and progression to end-stage renal disease.
7
Identifying these patients early and addressing modifiable risk factors is central to delaying renal complications such as diabetickidneydisease.
8
The protein kinase C (PKC)-beta isoform has been implicated to play a pivotal role in the development of diabetickidneydisease.
9
Methods: Randomized controlled trials comparing endothelin receptor antagonists with placebo in people with diabetickidneydisease were identified through PubMed, Embase and the Cochrane Library.
10
Previous studies suggest that systemic metabolic disorders such as hyperglycemia and dyslipidemia cause alterations of renal metabolism, leading to renal dysfunction including diabetickidneydisease.
11
Diabetickidneydisease (DKD) is a serious disease that presents a major health problem worldwide.
12
Diabetickidneydisease is a microvascular complication that is observed in a minority of patients with long-standing hyperglycemia.
13
Diabetickidneydisease (DKD) is a life-limiting condition characterized by progressive and irreversible loss of renal function.
14
Diabetickidneydisease causes significant morbidity and mortality among people with type 1 diabetes (T1D).
15
Diabetickidneydisease (DKD) remains the leading cause of end-stage renal disease (ESRD) and is therefore a major burden on the healthcare system.